3-[6-(2-ethoxybenzylamino)pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile | 1029044-74-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[6-(2-ethoxybenzylamino)pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile
• 英文别名: 3-[[6-[(2-ethoxyphenyl)methylamino]pyridin-3-yl]methyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile
• CAS: 1029044-74-3
• 化学式: C₂₃H₂₁N₅O
• 分子量: 383.453
• InChiKey: CYHLRNFVLAYZGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  86.6
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Compounds modulating c-fms and/or c-kit activity and uses therefor
  申请人：Zhang Jiazhong

  公开号：US20090076046A1

  公开（公告）日：2009-03-19

  Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.

  提供了对受体蛋白酪氨酸激酶c-kit和/或c-fms活性的化合物。还提供了用于治疗c-kit介导的疾病或病状和/或c-fms介导的疾病或病状的组合物，以及使用它们的方法。
• COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY
  申请人：Zhang Jiazhong

  公开号：US20110230482A1

  公开（公告）日：2011-09-22

  Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.

  本文提供了对受体蛋白酪氨酸激酶c-kit和/或c-fms活性化合物。还提供了用于治疗c-kit介导的疾病或状况和/或c-fms介导的疾病或状况的组合物，以及其使用方法。
• COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR
  申请人：Zhang Jiazhong

  公开号：US20120309756A1

  公开（公告）日：2012-12-06

  Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.

  本文提供了在受体蛋白酪氨酸激酶c-kit和/或c-fms上活性化合物。还提供了用于治疗c-kit介导的疾病或状况和/或c-fms介导的疾病或状况的组合物，并提供了其使用方法。
• Kinase modulation, and indications therefor
  申请人：Plexxikon Inc.

  公开号：US10123998B2

  公开（公告）日：2018-11-13

  The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof.

  本公开提供了使用蛋白激酶抑制剂治疗疾病和病症的方法，包括与选自Fms蛋白激酶（包括其任何突变）、Kit蛋白激酶（其任何突变）、Flt-3蛋白激酶（其任何突变）及其组合的任何蛋白激酶的活性相关的疾病和病症。
• KINASE MODULATION AND INDICATIONS THEREFOR
  申请人：PLEXXIKON INC.

  公开号：US20130274259A1

  公开（公告）日：2013-10-17

  Compounds, compositions and methods useful for treatment of Flt3-mediated diseases or conditions are provided herewith. Also provided herewith are methods for modulating the receptor protein tyrosine like kinase 3(Flt3).